The IXIARO vaccine. Valneva targets reliable Japanese encephalitis protection
Published on 07/19/2026 at 10:34 | Editorial responsibility: Rafael Müller, Editor-in-Chief AD HOC NEWS
IXIARO by Valneva lands in the clinic fridge with a quiet clink of glass, a small 0.5 ml vial that matters a lot to someone packing for Southeast Asia. The clear suspension looks almost mundane, but as Valneva CEO Thomas Lingelbach likes to remind investors, travel vaccines start protecting long before the boarding pass prints.
What IXIARO is designed to do
IXIARO is an inactivated Japanese encephalitis vaccine indicated for adults, adolescents, children and infants from 2 months of age, primarily traveling to or living in endemic areas across Asia and parts of the Western Pacific. The antigen is based on the attenuated SA14-14-2 strain, purified and inactivated, then adsorbed onto aluminum hydroxide as adjuvant, which gives the liquid a faintly opaque shimmer when the vial is swirled in the nurse’s hand.
The standard primary schedule consists of two 0.5 ml intramuscular injections, typically administered on day 0 and day 7 to 28, with a booster recommended for individuals who remain at risk, such as long-term expatriates or military deployments. One practical detail frequent travelers like, according to clinic staff in Vienna, is that IXIARO can be co-administered with several common travel vaccines, including hepatitis A and typhoid, as long as separate injection sites are used.
How IXIARO fits into Valneva’s specialty vaccine portfolio
Investors tracking Valneva SE stock can see IXIARO alongside cholera and chikungunya projects as part of the group’s travel and specialty vaccine strategy.
Dosing, formulation and handling
On the pharmacy shelf, IXIARO is supplied as a 0.5 ml suspension in a vial or pre-filled syringe, stored in the standard 2 to 8 °C cold chain alongside influenza and hepatitis vaccines. The formulation contains 6 micrograms of inactivated Japanese encephalitis virus antigen per dose, plus aluminum hydroxide, sodium chloride and trace residuals from the manufacturing process, a composition laid out in Valneva’s summary of product characteristics used by travel clinics.
A typical consultation runs like this: the nurse checks the itinerary, then pulls a cool glass vial of IXIARO from the refrigerator, letting a thin film of condensation collect as she explains that protective antibodies build up about one week after the second dose. For late planners flying in less than seven days, some travel medicine centers note that the compressed day 0 and day 7 schedule still beats flying unprotected into high-risk rural zones, although full immunogenicity data favors completing both doses before departure.
Who IXIARO is for and where it is sold
Valneva positions IXIARO squarely at travelers, military forces and residents with exposure to rice fields, pig farms or wetland habitats where the Culex mosquito vectors thrive. Public health authorities, including the US Centers for Disease Control and Prevention, highlight Japanese encephalitis as a low-incidence but high-impact disease, with case-fatality rates around 20 to 30 percent and a substantial risk of long-term neurological sequelae for survivors.
Commercially, IXIARO is marketed in North America, Europe and select Asia-Pacific markets through a mix of direct sales to hospitals and distribution via travel clinics and vaccination centers. In the United States, the product is licensed as IXIARO and recommended for travelers who plan to spend at least one month in endemic rural areas, especially during the transmission season, while in some European countries national travel medicine guidelines refer to the same inactivated vaccine under its global brand name.
Efficacy, safety and clinical data
Valneva built IXIARO on a data set of randomized controlled trials and post-marketing surveillance that regulators in the EU, US and other jurisdictions reviewed before approval. In pivotal studies, seroconversion rates after the two-dose primary series reached well above 90 percent, often quoted in the mid to high 90s, when measured by neutralizing antibody titers against the Japanese encephalitis virus, providing clinical confidence for physicians advising travelers headed to backpacker routes and military training grounds.
Safety-wise, IXIARO behaves like many other aluminum-adjuvanted inactivated vaccines, with typical local reactions such as injection site pain, redness and swelling, and systemic effects like headache or mild fever in a minority of recipients. During one Phase 3 extension study highlighted in Valneva’s investor materials, principal investigator Dr. Barbara Holub reported that serious adverse events were rare and not clearly vaccine-related, a finding that helped reassure both regulators and corporate partners supplying armed forces.
Competitive landscape in travel vaccines
On the product map, IXIARO sits alongside other Valneva travel and specialty vaccines such as Dukoral for cholera and a newer chikungunya candidate, but Japanese encephalitis remains a niche segment compared to flu or COVID-19. Yet for niche doesn’t mean irrelevant: analysts tracking Valneva noted years in which travel vaccine sales, including IXIARO, provided a stabilizing revenue base while pipeline projects moved through clinical phases.
Competition in Japanese encephalitis prevention includes live-attenuated vaccines used in endemic countries and other inactivated preparations manufactured by Asian producers, but IXIARO has carved out a space in Western travel medicine thanks to its regulatory approvals and data package. Swiss and German travel clinics often mention IXIARO by brand when discussing Japanese encephalitis with patients, reflecting how the name has become shorthand for the category in those markets.
Logistics, pricing and availability
From a logistics perspective, IXIARO slots into existing vaccine supply chains without exotic requirements: standard refrigerated transport, routine handling and single-use vials that fit the normal workflow of a busy travel clinic. Valneva, headquartered in France and with operational hubs in Austria and Sweden, uses regional distributors and direct agreements with healthcare providers to keep stock on hand during peak holiday seasons, when demand from backpackers and business travelers climbs.
Pricing varies by country and channel, but for many private-pay travelers the out-of-pocket price reflects not just the vaccine itself but also the consult time and administration fee charged by the clinic. Insurance coverage remains uneven; some occupational schemes cover IXIARO for employees sent to endemic field sites, while leisure travelers often pay themselves, a point consultants like Dr. Karin Leder in Melbourne raise when advising on total trip health budgets.
Regulatory status and labeling
Regulatory documents for IXIARO are publicly accessible through agencies such as the European Medicines Agency and national authorities, outlining indications, dosing schedules and contraindications in detail. These materials emphasize that IXIARO is contraindicated in individuals with known hypersensitivity to any component of the vaccine or to previous Japanese encephalitis vaccines, and caution is advised in people with acute severe febrile illness at the time of planned vaccination.
Labeling across markets stays broadly consistent, with minor language and formatting differences, but one constant is the warning that no vaccine offers 100 percent protection. Travel medicine specialists therefore pair IXIARO with non-pharmaceutical measures like insect repellents, long-sleeved clothing and bed nets, a holistic message that sticks better when the patient feels the cool wipe on their upper arm before the injection.
How IXIARO contributes to Valneva’s business
For Valneva, IXIARO represents a commercialized product in the specialty vaccine segment, contributing recurring revenue alongside other travel vaccines while the company advances newer candidates in other infectious disease areas. In past investor presentations, Thomas Lingelbach and his team have described IXIARO as part of a "sustainable vaccine portfolio" strategy, balancing licensed products and R&D programs to smooth volatility and support long-term value creation.
On European exchanges, the Valneva SE share (ISIN FR0013280286) is influenced by clinical milestones and regulatory decisions as much as by steady contributions from travel vaccines like IXIARO, which form a tangible, cash-generating base underneath the more speculative pipeline story.
IXIARO by Valneva SE at a glance
- Product: IXIARO
- Manufacturer: Valneva SE
- Category: Classic / Longseller travel vaccine
- Market launch: Mid-2000s, after regulatory approvals in the EU and US
- MSRP / Price: Typically billed per dose in local currency; final consumer price depends on clinic fees and country-specific reimbursement
- Availability: Travel clinics, hospitals and vaccination centers in North America, Europe and selected Asia-Pacific markets
- Target group: Travelers, military personnel and residents with exposure to Japanese encephalitis risk areas
- Highlight / USP: Inactivated Japanese encephalitis vaccine with a two-dose primary series and booster option for ongoing exposure
Disclaimer regarding our articles: No investment advice, no buy or sell recommendation. Information on prices, companies, and markets is provided without guarantee; changes are possible at any time. Stock market transactions can lead to substantial losses. Our articles are created and reviewed in whole or in part automatically with the support of AI.
